Product Description
Mechanisms of Action: D2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Bulgaria | Canada | Colombia | Czech | Denmark | Dominican Republic | Egypt | France | Germany | Greece | Hungary | Ireland | Italy | Jordan | Luxembourg | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Turkey | Ukraine | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Endometriosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
RAQUEL | P2 |
Completed |
Endometriosis |
2022-02-14 |
49% |